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Objective. To evaluate leukocyte gene expression for 9 selected genes (mRNAs) as biological markers in patients with medication
refractory depression before and after treatment with ECT or isoflurane anesthesia (ISO). Methods.I nas u b s t u d yo fa
nonrandomized open-label trial comparing effects of ECT to ISO therapy, blood samples were obtained before and after treatment
from 22 patients with refractory depression, and leukocyte mRNA was assessed by quantitative PCR. Patients’ mRNAs were also
compared to 17 healthy controls. Results. Relative to controls, patients before treatment showed significantly higher IL10 and DBI
and lower ADRA2A and ASIC3 mRNA (𝑃 < 0.025). Both ECT and ISO induced significant decreases after treatment in 4 genes:
IL10,NR3C1, DRD4, and Sult1A1. After treatment, patients’ DBI, ASIC3, and ADRA2A mRNA remained dysregulated.Conclusion.
Significant differences from controls and/or significant changes after ECT or ISO treatment were observed for 7 of the 9 mRNAs
studied. Decreased expression of 4 genes after effective treatment with either ECT or ISO suggests possible overlap of underlying
mechanisms. Three genes showing dysregulation before and after treatment may be trait-like biomarkers of medication refractory
depression.Geneexpressionforthesepatientshasthepotentialtofacilitatediagnosis,clarifypathophysiology,andidentifypotential
biomarkers for treatment effects.
1. Introduction
Blood-basedbiomarkersareimportanttotheunderstanding,
diagnosis, and treatment of medical disorders. They can be
especially helpful when the disorder is poorly understood,
complex, or where the differentiation of subgroups may
have important implications for treatment and long-term
outcomes. In the case of depressive disorders (DD), one
subgroup where biomarkers would be especially useful con-
sists of those patients who are refractory to pharmacologic
antidepressanttherapies.Previousstudieshavesuggestedthat
gene expression (mRNA) on white blood cells may provide
useful biomarkers for patients with DD, including those with
refractory depression [1, 2].
Patients with medication refractory depression (typically
defined by failure to achieve remission with two or more
trials of different antidepressant regimens) represent almost
one-third of all patients with DD [3]. There are relatively
few treatment options for these patients. Electroconvulsive
therapy (ECT) is widely acknowledged to be the most
effective option, achieving remission in 55–90% of the cases,
even among patients who were previously refractory [4, 5].
D e s p i t ei t ss a f e t ya n de ffi c a c y[ 6], many millions of patients
with refractory DD elect not to receive ECT due, in large
part, to misperceptions about this treatment being painful
or traumatic or to concerns regarding associated adverse
cognitive effects, most of which are, however, temporary
[7,8].Thishasencouragedeffortstofindalternativetherapies
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to ECT that are effective in treating medication refractory
DD, in addition to having greater social acceptability and
minimal adverse effects on memory and cognitive function.
One alternative therapy originally proposed two decades ago
is high dose inhalation anesthesia using isoflurane (High
ISO). Like ECT, High ISO induces a brief state of elec-
trocortical quiescence (burst suppression, BS), but does so
withoutinducingtheECTseizureortheadversememoryand
cognitive symptoms. Langer et al. first reported that a series
of 6 treatments with High ISO had similar efficacy to 6 ECT
sessions in reducing depressive symptoms without causing
memory loss [9, 10]. Further research on the antidepressant
effects of ISO or sevoflurane yielded mixed results. Positive
antidepressant effects of High ISO were reported by Carl et
al. [11]a n dE n g e l h a r d te ta l .[ 12]. In contrast, Greenberg et al.
[13]reportedlittleimprovementwithHighISOtreatmentsin
6elderlydepressedpatients,andGarc´ ıa-Toroetal.[14]fo und
onlylimitedimprovementafter4prolongedtreatmentsoflow
dose sevoflurane (24% reduction in depressive symptoms).
There was essentially a cessation of interest in this poten-
tial alternative treatment until recently, when our research
group completed an open-label study comparing ECT versus
High ISO inducing BS [15]. We suggested that the previous
unsuccessful studies used too few treatments when, indeed,
even the gold standard intervention, ECT, requires 8–12
treatments for maximal effectiveness. Also, we hypothesized
that anesthetic treatment at doses that are too low to produce
strong cortical BS (like the sevoflurane dose used by Garc´ ıa-
Toro et al. [14]) would have minimal antidepressant effects.
Thus, we compared responses of 8 patients with medication
refractory depression treated with 10 sessions of High ISO
with confirmed BS to 20 patients treated with bifrontal ECT.
Our findings showed that High ISO led to an antidepressant
response defined as a 50% reduction on the Hamilton rating
scale of depression (HRSD score) in 75% of patients and
an identical rate of full remission of depressive symptoms
as ECT (50%). Also, using standardized neuropsychological
tests of memoryandprocessing speed, ECT led to temporary
declines in cognitive function and more lasting deficits in
autobiographical memory, but 10 treatments with high ISO
did not.
As a pilot substudy ancillary to our open-label study [15]
comparing High ISO/BS versus ECT treatment, we sought
to evaluate the utility of using leukocyte gene expression
as a biomarker of disease for this medication refractory
group of DD patients. Our aims were to improve our
understanding of the pathophysiology of refractory DD
and to assess whether any changes induced by the two
different treatments were similar or different. Thus, we
obtained blood samples from 22 of the patients with med-
ication refractory DD for determination of leukocyte gene
expression at both Pretreatment and Post-treatment (24–48
hours after the final treatment session). We also obtained
blood samples from 17 healthy, nondepressed controls. We
examined a profile of 9 mRNAs, consisting of immune
marker IL10; adrenergic receptor ADRA2A; hypothalamic-
pituitary-adrenal (HPA) axis associated receptors includ-
ing the glucocorticoid receptor (NR3C1), dopaminergic
receptor-4 (DRD4), and diazepam-binding inhibitor (DBI,
aka the GABA receptor modulator). We also included the
sulfotransferase family cytosolic 1a (Sult1A1) involved in the
metabolism of monoamines and drugs. For a transcription
gene linked to multiple levels of cellular regulation and
metabolism, we included VEGFA, previously shown to differ
in patients with major depressive disorder (MDD) compared
to controls [16]. Finally, we included two ion channel recep-
tors of the acid sensing ion channel (ASIC) family. These
ion channel genes were selected based on prior research
in our laboratory showing associations with chronic fatigue
syndrome and fibromyalgia [17, 18], animal models showing
associationswithdepression[19],a n dmRN Ainpos tm o rt em
tissue[20].AmongthebehavioralfunctionsrelevanttoMDD
linked to ASIC pathways are anxiety, aggression, and pain
[21].
Ourobjectivesforthissmallpilotstudyweretodetermine
(1) whether patients with refractory DD would differ from
controls in expression of selected target genes prior to treat-
ment, (2) whether 10 treatment sessions of High ISO and 8–
12 sessions of ECT would induce similar or different changes
in expression of these target genes, and (3) whether some
genes would show persistent differences in these patients
from levels in controls even after treatment, indicating that
these may be trait-like biomarkers of refractory DD.
2. Materials and Methods
The study protocol was approved by the University of Utah
InstitutionalReviewBoard(IRB)andallsubjectsgavewritten
consent prior to participation.
2.1. Subjects. Subjects in the DD group included 22 patients
(14F/8M, mean age 40.00 ± 2.44) with medication refractory
depression who had been referred for consultation for possi-
bleelectroconvulsivetherapy(ECT)totheUniversityofUtah
Neuropsychiatric Institute (UNI). Patients were diagnosed
according to the criteria in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) [22].
Seventeen met criteria for major depressive disorder (MDD)
and 5 for with bipolar disorder (BPD), with current phase
being moderate to severe depression. Exclusion criteria have
been described previously [15]. Demographic and clinical
parameters for patients are listed in Table 1.
Thesepatientsrepresentthemajority(78.6%)ofthemed-
ication refractory DD participants from a nonrandomized,
open-label study comparing the cognitive side effects and
treatment efficacy of High ISO anesthesia versus ECT [15].
Blood samples were collected before the start of High ISO
or ECT treatments (pretreatment) and 24 hours after the
last treatment session (posttreatment). The original study
included 28 patients: 20 patients who elected to receive ECT
and 8 patients who elected to receive High ISO. Of the
20 ECT patients, 5 patients received treatment before the
gene expression ancillary study began, and 1 patient had
a blood sample that did not meet quality standards (not
enough total RNA). This left 14 ECT subjects that were
includedintheanalysis.InourECTsample,onepatienthada
pretreatment blood sample but no posttreatment sample. AllDepression Research and Treatment 3
Table 1: Demographic and medical data for controls (CON) and depressive disorder (DD) patients at pretreatment.
CON ECT ISO All DD (ECT + ISO)
Number of subjects 𝑛 = 17 𝑛 = 14 𝑛 = 8 𝑛 = 22
Age (years) 47.5 ± 3.15 40.9 ± 3.2 38.5 ± 4.0 40.0 ± 2.3
a
Gender: male/female 6/11 9/5 5/3 14/8
Diagnosis: MDD/BPD — 11/3 6/2 17/5
Inpatient/outpatient — 7/7 0/8 7/15
Number of treatments — 9.9 ± 0.4 9.6 ± 0.4 9.8 ± 0.3
HRSD pretreatment — 35.6 ± 1.8 26.6 ± 1.4 32.3 ± 1.5
HRSD posttreatment — 12.7 ± 2.5
b 12.5 ± 3.6
b 12.6 ± 2.0
b
QIDS pretreatment — 18.7 ± 1.2 17.0 ± 0.8 18.0 ± 0.8
QIDS posttreatment — 13.3 ± 1.3
c 9.9 ± 1.4
c 11.8 ± 1.0
c
No medication 17 2 2 4
Any antidepressants (classes below) 0 11 (78.5%) 5 (62.5%) 16 (72.7%)
SSRIs 0 5 2 7
NRI 0 1 0 1
SNRI 0 6 3 9
Tricyclic 0 0 0 0
Anticonvulsants (none, stopped, continued) 0 4/4/6 4/2/2 8/6/8
Antipsychotics 0 4 5 9
aA g ew a sm a r g i n a l l yl o w e ri nA l lD Dc o m p a r e dt oC O Ng r o u p( 𝑃 = 0.06), and thus was included as a covariate in all subsequent analyses where it was related
to the outcome measure (at least 𝑃 < 0.10).
bHRSD was significantly decreased at Post compared to Pre (ECT 𝑃 < 0.001,I S O𝑃 < 0.01).
cQIDS was significantly decreased at Post compared to Pre (ECT 𝑃 = 0.0046,I S O𝑃 = 0.0011).
SSRI (selective serotonin reuptake inhibitor), NRI (norepinephrine reuptake inhibitor), SNRI (mixed serotonin-norepinephrine reuptake inhibitor).
8patientsreceivingISOhadacceptablebloodsamplesatboth
pretreatment and posttreatment.
The 14 ECT patients received 8–12 treatments, while the
8 ISO patients received 10 treatments [9, 10, 15]. Clinical
assessment at pretreatment and posttreatment was carried
out using the Hamilton rating scale for depression (HRSD-
24), a structured clinician-administered interview [23, 24].
Depressionseveritywasalsoassessed priortoeachtreatment
sessionusingthequickinventoryofdepressivesymptomatol-
ogy (QIDS) self-report. The QIDS self-report has been found
to have concurrent validity with the HRSD [25]. Patients
with the most severe depression more frequently elected
ECT versus ISO; thus, the pretreatment HRSD mean value
was higher in the ECT versus the ISO group. For all DD
participants, the decision was made to maintain pretreat-
ment antidepressant, antipsychotic, and other psychoactive
medications throughout the study. Specific medications are
noted in Table 1.O fn o t e ,s o m ep a t i e n t sw e r ea s k e dt os t o p
anticonvulsant medications prior to treatment. Otherwise,
medicationregimenswerenotalteredproximatetotreatment
and testing.
Controls included 17 subjects (11F/6M, mean age 47.53 ±
3.1). These participants provided medical history informa-
tion including all current medications and completed the
QIDS-SR. None were taking antidepressants or had current
symptoms or history of depression.
2.2.mRNAExtractionandAnalysis. Allbloodprocessingand
analyses were performed by personnel being blinded to the
subjects’ group. Blood was collected in EDTA tubes and kept
on ice, andwithin15 minutesafter collectionwas centrifuged
at3200rpm(1315×g-ClayAdamsCompactIICentrifuge)for
12 minutes. The plasma was removed, and the white layer
carefully collected in RLT+𝗽-ME (Qiagen, Valencia, CA),
then quickly frozen using a methanol-dry ice slurry and
stored at −80
∘C. RNA was extracted using RNeasy mini kits
(Qiagen, Valencia, CA) and treated with RNase-free DNase-
I (Qiagen, Valencia, CA). Immediately following extraction,
RNA was converted to a cDNA library using the ABI
High Capacity cDNA Archive Kit (Applied Biosystems/Life
Technologies, Inc., Foster City, CA), and then treated with
RNase-H (Epicentre Biotechnologies, Madison, WI). The
cDNA samples were stored at −20
∘Cu n t i la n a l y s i s .R N A
integrity was assessed with a Bioanalyzer and consistently
found to have RIN values (RNA integrity numbers) greater
than 9. The cycle counts for the control gene, TF2B, averaged
21.78 ± 1.67 (SD) for control subjects and 22.32 ± 2.09 (SD)
for patients, Student’s 𝑡-test 𝑃 = 0.12.W es e l e c t e dT F 2 B
a st h ep r e f e r r e dc o n t r o lg e n ea n dh a v ev e r i fi e dt h a tT F 2 B
qPCR counts do not change in freshly harvested separated
human leukocytes under a variety of conditions, when RNA
is processed as described here.
The cDNA libraries were analyzed using the ABI quan-
titative, real-time PCR system on the ABI Prism 7900
Sequence Detection System (SDS) 2.4.1 (Applied Biosystems,
Inc., Foster City, CA), using ABI TaqMan Master Mix
(Applied Biosystems, Inc., Foster City, CA). Master mix/
primer plus primer/probe solutions and template solu-
tions were separately loaded onto 96-well preplates. Then
384-well plates were robotically loaded and mixed from4 Depression Research and Treatment
the 96-well plates. Each targeted gene was examined in
duplicate, with TF2B standards being run in quadruplicate.
Additional control samples containing no template were
also run. Primer probes for the 9 genes were obtained
from TaqMan Gene Expression Assays (Applied Bio-
systems, Inc., Foster City, CA) and were as follows: Adren-
ergic A2A—Hs00265081 s1; ASIC1—Hs00241630 m1;
ASIC3—Hs00245097 m1; diazepam binding inhibitor—
Hs00220950 m1; dopamine receptor 4—Hs00609526 m1;
glucocorticoid receptor NR3C1—Hs01005217 m1; IL10—
Hs00174086 m1; sulfotransferase 1A1—Hs00738644 m1; vas-
cular endothelial growth factor A—Hs99999070 m1; and
control primer probe TF2B—Hs00155321 m1q.PCRdatawas
p r o c e s s e du s i n gt h eS D S 2p r o g r a mf r o mA p p l i e dB i o s y s t e m s
w i t hc o u n tv a l u e sf o rg e n e sc o m p u t e di nt h ec u rv el o g - l i n e a r
using a standard 0.2 threshold. Gene expression amounts
were determined using the 2
−Δ𝑇 method, where Δ𝑇 is the
count difference of the candidate gene from TF2B.
2.3. Statistics. All statistical tests were performed using
STATA ver.12 statistical software. Demographic variables
were compared using Student’s 𝑡-test for metric variables
and Pearson 𝜒
2 for nominal variables. HRSD and QIDS data
were analyzed with repeated measures ANCOVAs (2×2
treatment group × time for HRSD and 2×8treatment group
× time for QIDS) with age as a covariate, to compare ECT
andISOtreatmentgroupsatpretreatmentandposttreatment
andtoexaminechangesindepressionseveritybetweenthose
time points. Age was retained in the final model only if
it approached significance (𝑃 < 0.10). Gene expression
valueswere logtransformedinorderto satisfynormalityand
equality of variance assumptions. For each gene, repeated
measures ANCOVAs (2×2treatmentgroup× time)withage
as a covariate were used to compare ECT and ISO treatment
groups at pretreatment and posttreatment and to examine
changes in gene expression between those two time points.
One of the 14 ECT patients who did complete the HRSD and
QIDS assessments did not have a posttreatment blood draw.
For the repeated measures gene expression analyses where
data were missing, the more conservative decision was made
t ou s et h er e d u c e ds a m p l es i z er a t h e rt h a nu s er e g r e s s i o n -
based methods to interpolate the missing values. When no
significant main effect of treatment group or group × time
interactionwasobtainedbuttheeffectoftimewassignificant,
data from both the ECT and ISO groups were combined into
a single DD group for comparison of differences between
pretreatment and posttreatment levels. As a second level of
analysis, these same pretreatment and posttreatment levels
from the DD group were compared to the levels obtained
from controls. Cohen’s 𝑓 effect sizes were computed for
ANOVAmodelswith0.02,0.15,and0.35interpretedassmall,
moderate,andlargeeffectsizes,respectively.Statisticalvalues
are reported as one-tailed tests for differences involving a
priori hypotheses (differences between patients and controls
andchangesfrompretreatmenttoposttreatment),becausein
apilotstudy,thereisagreaterconsequenceforTypeIIversus
Type I error. All other tests were two-tailed. As a correction
for multiple comparisons, alpha level for analyses involving
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Figure 1: ECT and ISO display progressive improvements on quick
inventory of depression scale (QIDS) self-report taken prior to each
treatment.ECTpatientsareinsolidsquaresandISOpatientsinopen
triangles. Both treatment groups display progressive improvement
over the 10 treatments. As described in the demographics table, all
ISO patients received 10 treatments and completed their QIDS-SR
prior to each treatment. Conversely, 11/14 ECT patients completed
their QIDS. For data at treatments 9 and 10, there were 10 and
7 patients, respectively, in the ECT group. The slight upturn at
treatments 9 and 10 in the ECT group is the result of the more
severely depressed patients requiring those final treatments.
a l lD Dp a t i e n t sv e r s u sc o n t r o l sw a ss e ta t𝑃 < 0.025 rather
than 𝑃 < 0.05.
3. Results
3.1. Depression Severity Decreases following ECT and ISO.
Consistent with our prior report from the full patient
sample [15], in this subsample, the ECT patients displayed
significantly higher pretreatment HRSD depression severity
compared to the ISO group (𝑡 = 3.90, 𝑃 < 0.01).
Both ECT patients and ISO patients displayed significant
HRSD improvement at posttreatment relative to pretreat-
ment(paired𝑡 = 7.50,𝑃 < 0.001forECT;paired𝑡 = 3.61,𝑃<
0.01 for ISO). Based on self-reported depressive symptoms
using QIDS scores obtained prior to each treatment session,
patientsintheECTandISOgroupsdidnotdifferatanytime,
andbothgroupsshowedprogressiveimprovementduringthe
treatmentsessions(seeFigure 1).Sinceallpatientsreceivedat
least 8 treatment sessions, repeated measures analysis based
on the first 8 QIDS scores showed no significant differences
between treatment groups (𝑃 = 0.972) and no significant
group × time interaction (𝑃 = 0.6084); however, the main
effect of time on QIDS scores was significant (𝐹(1,173) =
13.11, 𝑃 < 0.00001;C o h e n ’ s𝑓 effect size = 0.4376).
SubsequentcontrastsindicatedamarginallysignificantQIDS
score decrease from session 1 to session 3 (𝑃 = 0.064)a n d
significant decreases from session 1 to sessions 4–8 (𝑃<
0.0003–𝑃 < 0.00001).Depression Research and Treatment 5
Table 2: Pretreatment gene expression in controls (CON), ECT, and ISO Groups.
Gene CON (𝑛=1 7 )E C T ( 𝑛=1 4 )I S O ( 𝑛=8 )
CON versus DD
(ECT + ISO)
P value
CON versus
ECT
P value
CON versus
ISO
P value
ECT versus
ISO
P value
ADRA2A
∗ 5.26𝐸 − 03 2.12𝐸 − 03 1.91𝐸 − 03
0.0013 0.001 0.0285 0.541
±1.25𝐸 − 04 ±5.27𝐸 − 04 ±4.81𝐸 − 04
ASIC1 7.98𝐸 − 04 1.02𝐸 − 03 1.01𝐸 − 03
0.367 0.303 0.137 0.518
±1.08𝐸 − 04 ±2.03𝐸 − 04 ±1.52𝐸 − 04
ASIC3 8.32𝐸 − 03 6.01𝐸 − 03 5.54𝐸 − 03
0.003 0.0055 0.0065 0.684
±7.39𝐸 − 04 ±4.63𝐸 − 04 ±3.52𝐸 − 04
DBI 3.96𝐸 − 03 5.59𝐸 − 03 5.60𝐸 − 03
0.0004 0.001 0.003 0.979
±2.99𝐸 − 04 ±3.84𝐸 − 04 ±5.85𝐸 − 04
DRD4 1.84𝐸 − 03 2.26𝐸 − 03 2.29𝐸 − 03
0.927 0.466 0.476 0.992
±2.54𝐸 − 04 ±5.22𝐸 − 04 ±5.92𝐸 − 04
IL10 5.70𝐸 − 03 1.22𝐸 − 02 1.25𝐸 − 02
0.022 0.024 0.035 0.910
±7.78𝐸 − 04 ±4.36𝐸 − 03 ±3.92𝐸 − 03
NR3C1 7.90𝐸 − 01 7.05𝐸 − 01 7.15𝐸 − 01
0.465 0.285 0.255 0.860
±7.40𝐸 − 02 ±5.39𝐸 − 02 ±1.10𝐸 − 01
SULT1A1 1.44𝐸 − 03 1.56𝐸 − 03 1.26𝐸 − 03
0.778 0.196 0.254 0.195
±1.20𝐸 − 04 ±1.44𝐸 − 04 ±1.20𝐸 − 04
VEGFA 7.53𝐸 − 02 8.44𝐸 − 02 7.02𝐸 − 02
0.971 0.301 0.193 0.217
±5.49𝐸 − 03 ±9.71𝐸 − 03 ±1.31𝐸 − 03
Data shown as means ± SE and depict raw data; ANOVA statistics and contrasts used log-transformed data.
Age and male covariates were not significant and not included.
∗Includes age as covariate.
Expressed in scientific notation units where 𝐸+0 1= ×10, 𝐸+0 0= ×1, 𝐸−0 1= ×0.1, 𝐸−0 2= ×0.01, and so forth.
3.2. Gene Expression Differences in ISO and ECT Groups
a n dC o m b i n e dD DG r o u pv e r s u sC o n t r o l s .Initial ANCO-
VAs revealed no significant pretreatment mRNA differences
between the ECT and ISO treated patients (all P’s > 0.19;
see Table 2). When the pretreatment mRNA levels of the
combined DD patients were compared to levels shown by
controls, significant differences were obtained for 4 genes:
the adrenergic receptor ADR2A (𝐹 = 23.55, 𝑃 = 0.0013,
and Cohen’s 𝑓 = 0.437), the acid sensing ion channel ASIC3
(𝐹 = 10.39, 𝑃 = 0.003,a n dC o h e n ’ s𝑓 = 0.511), the
GABA receptor modulator DBI (𝐹 = 15.29, 𝑃 < 0.0004,a n d
Cohen’s 𝑓 = 0.613), and the cytokine IL10 (𝐹(1,36) = 5.77,
𝑃 = 0.022,a n dC o h e n ’ s𝑓 = 0.354). Subsequent compar-
isons among means showed that the separate ECT and ISO
patient subgroups had significantly decreased expression of
ADRA2A and ASIC3 and significantly increased expression
of DBI and IL10 at pretreatment compared to controls (see
Table 2). The consistency of these findings in both treatment
groups strengthened our confidence in the mRNA similarity
of the two patient groups prior to receiving treatment.
3.3. Gene Expression in ISO versus ECT Groups at Pretreat-
ment versus Posttreatment. In our second set of analyses
whereposttreatmentandpretreatmentlevelswerecompared,
the ANCOVAs revealed no significant main effect of treat-
ment group or group × time interactions for any of the
9 genes (see Table 3). Thus, there no mRNA differences
between the ECT and ISO groups either at posttreatment or
at pretreatment. However, there were significant main effects
of time (pre- versus posttreatment differences) for 4 genes:
DRD4 (𝐹(1,19) = 3.72, 𝑃 = 0.035,C o h e n ’ s𝑓 = 0.137),
IL10 (𝐹 = 4.57, 𝑃 = 0.025,a n dC o h e n ’ s𝑓 = 0.111), NR3C1
(𝐹 = 21.63, 𝑃 < 0.001,a n dC o h e n ’ s𝑓 = 0.379), and
Sult1A1 (𝐹 = 3.55, 𝑃 = 0.041,a n dC o h e n ’ s𝑓 = 0.169).
Subsequent contrasts between paired means showed that all
these4genesdecreasedsignificantlyatposttreatmentrelative
topretreatment;notethatboththeISOandECTgroupsshow
these same treatment-related changes in expression of these
4 genes (see Table 3). These findings indicate that changes
in expression of some of the genes under study did occur
between pretreatment and posttreatment and these changes
w e r en o tu n i q u et oe i t h e rE C To rI S Ob u ts i m i l a ri nb o t h
treatment groups. For expression of one gene, VEGFA, there
wasamarginaltrendforagroup×timeinteraction(𝐹 = 2.49,
𝑃 = 0.067,C o h e n ’ s𝑓 = 0.194), suggestive of a possible
exception to the general pattern of similar effects of the two
treatments.
It is also notable that of the 4 genes that differed in DD
patients versus controls, 3 were not significantly changed
from pretreatment to posttreatment: ADR2A, ASIC3, and
DBI. When posttreatment levels of these genes were then
compared to mRNA levels of controls, our comparisons
revealed that similar to pretreatment, DD patients continued
to have significantly higher DBI mRNA (5.48𝐸 − 03 versus
3.96𝐸 − 03, 𝐹 = 16.00, 𝑃 < 0.001,a n dC o h e n ’ s𝑓 = 0.664),
lower ADRA2A (2.95𝐸 − 03 versus 5.26𝐸 − 03, 𝐹 = 10.66,6 Depression Research and Treatment
Table 3: Gene expression for all 9 target genes at pretreatment versus posttreatment: means and ANCOVA outcomes for effects of treatment
group (ECT versus ISO), sample time (pre- versus posttreatment) and group × time interactions.
Gene ECT pre ECT post ISO pre ISO post Group
P value
Time
P value
Group × time
P value
ADRA2A 2.26𝐸 − 03 3.21𝐸 − 03 1.90𝐸 − 03 2.46𝐸 − 03
0.731 0.430 0.137
±6.26𝐸 − 04 ±8.12𝐸 − 04 ±5.70𝐸 − 04 ±1.29𝐸 − 03
ASIC1 9.46𝐸 − 04 1.24𝐸 − 03 1.01𝐸 − 03 1.12𝐸 − 03
0.995 0.390 0.162
±2.17𝐸 − 04 ±3.04𝐸 − 04 ±1.52𝐸 − 04 ±1.99𝐸 − 04
ASIC3 6.25𝐸 − 03 6.60𝐸 − 03 5.54𝐸 − 03 6.40𝐸 − 03
0.925 0.187 0.412
±5.16𝐸 − 04 ±5.87𝐸 − 04 ±3.52𝐸 − 04 ±9.60𝐸 − 04
DBI 5.49𝐸 − 03 5.39𝐸 − 03 5.67𝐸 − 03 5.62𝐸 − 03
0.904 0.492 0.436
±4.60𝐸 − 04 ±2.31𝐸 − 04 ±6.70𝐸 − 04 ±7.11𝐸 − 04
DRD4 2.23𝐸 − 03 1.68𝐸 − 03 2.29𝐸 − 03 1.69𝐸 − 03
0.874 0.035 0.341
±5.63𝐸 − 04 ±4.61𝐸 − 04 ±5.92𝐸 − 04 ±4.56𝐸 − 04
IL10 1.31𝐸 − 02 8.08𝐸 − 03 1.38𝐸 − 02 1.31𝐸 − 02
0.687 0.025 0.133
±5.69𝐸 − 03 ±2.73𝐸 − 03 ±4.26𝐸 − 03 ±4.16𝐸 − 03
NR3C1 6.83𝐸 − 01 4.90𝐸 − 01 7.44𝐸 − 01 5.63𝐸 − 01
0.953 0.00015 0.389
±7.44𝐸 − 02 ±4.48𝐸 − 02 ±1.22𝐸 − 01 ±8.88𝐸 − 02
SULT1A1 1.64𝐸 − 03 1.43𝐸 − 03 1.29𝐸 − 03 1.14𝐸 − 03
0.177 0.041 0.343
±1.76𝐸 − 04 ±1.61𝐸 − 04 ±1.36𝐸 − 04 ±6.24𝐸 − 05
VEGFA 9.03𝐸 − 02 8.15𝐸 − 02 7.02𝐸 − 02 8.81𝐸 − 02
0.977 0.295 0.067
±1.04𝐸 − 02 ±1.30𝐸 − 02 ±1.31𝐸 − 02 ±8.65𝐸 − 03
Data shown as means ± SE and depict raw data; ANCOVA used log-transformed data.
Expressed in scientific notation units, where 𝐸+0 1= ×10, 𝐸+0 0= ×1, 𝐸−0 1= ×0.1, 𝐸−0 2= ×0.01, and so forth.
𝑃 = 0.014,a n dC o h e n ’ s𝑓 = 0.170), and marginally lower
ASIC3 mRNA (6.72𝐸 − 03 versus 8.32𝐸 − 03, 𝐹 = 3.19, 𝑃=
0.08,a n dC o h e n ’ s𝑓 = 0.246). In contrast, at posttreatment,
IL10 was no longer increased in DD patients versus controls
(𝐹 = 2.35, 𝑃 = 0.136,a n dC o h e n ’ s𝑓 = 0.199). Additionally,
patients displayed decreased glucocorticoid receptor NR3C1
expressioncomparedtocontrolsatposttreatment(5.20𝐸−01
versus 7.90𝐸 − 01; 𝐹 = 8.70, 𝑃 = 0.006,a n dC o h e n ’ s𝑓=
0.476), although expression of this gene was not significantly
increased in DD patients at pretreatment.
4. Discussion
4.1. Effects of Isoflurane Anesthesia and ECT Treatment on
Gene Expression. There are two principal findings of this
pilot gene expression study. (1) Four of the 9 genes studied
showed significantly decreased expression at posttreatment
compared to pretreatment, and all these 4 genes changed
similarly after both the ECT and ISO treatment conditions.
Thisfindingsuggeststhatthese4physiologicalpathwayswere
altered in the same way by both of these effective antidepres-
sant treatment regimens, and that these changes may reflect
common mechanisms underlying the beneficial symptom
improvement. The genes in question were the dopamine
receptor DRD4, the cytokine IL10, the glucocorticoid recep-
tor NR3C1, and the enzyme Sult1A1. Of these 4 genes, only
IL10 was also significantly elevated at pretreatment in these
medication refractory DD patients compared to controls.
(2) Compared to healthy control participants, DD patients
had increased GABA receptor modulator DBI and decreased
adrenergic receptor ADRA2A and ASIC3 expression at
pretreatment that remained dysregulated after treatment,
despite depressive symptom improvement as reflected in
HRSD and QIDS scores. Although our sample sizes are
q u i t es m a l la n dt h u st h e s efi n d i n g sr e m a i np r e l i m i n a r y ,i t
was reassuring to see that when the ECT and ISO patient
subgroups were examined separately; these differences from
controls were significant in both groups (Table 2). Thus, our
preliminary interpretation is that these 3 mRNAs may be
trait-likebiomarkersofmedicationrefractorydepressionand
mayindicatephysiologicalpathwaysthatcouldpotentiallybe
linked to subsequent susceptibility to relapse.
Despite over 70 years of clinical use, the precise bio-
logical mechanisms underlying the antidepressant effects of
ECT are not fully understood. Changes in cerebral blood
flow, electrical activity of the cortex, monoamine effects,
inflammation,growthfactors,andneurogenesishaveallbeen
proposed [26–30]. Many of these elements are combined
in the “anticonvulsant theory” of ECT’s effects. This theory
asserts that with each successive ECT treatment and each
inductionofaseizure,therearesecondarychangesthatoccur
to raise the seizure threshold and minimize the seizures,
including long-lasting changes in seizure threshold, cerebral
blood flow, and the patterns of electrical activity of the
cortex, as well as changes in the release of neurotransmitters
and neuropeptides [31]. One strength of this theory is that
it accounts for why multiple ECT treatment sessions are
necessary. To date, however, there are no compelling dataDepression Research and Treatment 7
confirming or invalidating the correctness of these hypo-
thetical mechanisms. However, recent studies have shown
that preconditioning with isoflurane and other anesthetics
has neuroprotective effects against later ischemic events that
involve multiple mechanisms which appear to overlap with
components of this theory of ECT’s effects [32].
The potentially important role of cortical EEG burst
suppression in producing antidepressant effects of ECT or
anesthesia was first proposed by Langer et al. as they justified
their pioneering investigation of isoflurane treatments as
an alternative to ECT [9, 10]. Their rationale was that the
reduction in electrocortical activity was the feature shared by
HighISOandECT.Kranasteretal.reportedthattheBSindex
correlated with seizure duration in ECT treatments and thus
would be a useful predictor of antidepressant effectiveness
[33]. This interpretation has not previously been studied in
any rigorous way in humans but has been reinforced by
recent findings using animal models of depression. Research
in rats by Murrell et al. indicated that isoflurane had greater
potency to induce EEG BS than two related anesthetic
drugs, sevoflurane and desflurane, and that another inhaled
anesthetic, halothane, did not induce BS [34]. Using the
learned helplessness behavioral model of depression in rats,
Wang and colleagues found that 2 hours of isoflurane at 2%
prevented this depressive behavior, while anesthetic-naive or
halothane-treated rats showed no preventive antidepressant
effects [35].
Whether cortical burst suppression is the underlying
mechanism for the antidepressant effects of ECT or ISO
anesthesia is still an open and important research question
to address. The findings of the present study, however, do
support the hypothesis that ECT and ISO anesthesia treat-
ments may have similar effects on a number of neural and
immune pathways that could contribute to the reduction in
depressive symptoms observed in bothtreatmentconditions.
All four genes that were significantly decreased after ECT
were similarly decreased after high dose ISO treatments.
Decreases in expression of the glucocorticoid and dopamine
receptorsNR3C1andDRD4andintheexpressionofSult1A1,
an enzyme that promotes the breakdown of neurotransmit-
ters, neuropeptides, and hormones, might be predicted by
the anticonvulsant theory of ECT’s effects. Also, decreases in
expressionofseveralcytokines(butnotIL10)havepreviously
beenreportedfollowingapositiveresponsetoantidepressant
treatment with escitalopram or nortriptyline in the large
GENDEP investigation [1]. It should be noted that in the
current study, we examined gene expression changes 24
hours after the last treatment and therefore patients had
hereto received 8–12 treatments over the span of 2-3 weeks.
Therefore, changes may represent an acute response (from
the treatment 1-2 days before), as well as a response to
prolonged exposure to treatment. Also, expression of one
gene, VEGFA, showed a trend for a differential effect of ECT
versus ISO treatment (𝑃 = 0.067), an effect that might
have been significant if our sample size had been larger.
Future research with larger, randomized samples and larger
gene arrays are needed to verify whether ECT and ISO
effects on depression primarily involve the same or different
physiological pathways.
4.2.FunctionsofGenesThatShowTreatment-RelatedChanges.
We observed that patients had elevated levels of the anti-
inflammatory cytokine IL10 at pretreatment that were sig-
nificantly reduced at posttreatment. Cytokines are important
signaling molecules produced by the brain and immune cells
to induce inflammation in response to stress and foreign
pathogens. A wealth of previous research has implicated the
immune dysregulation in DD patients including elevated
levels of specific cytokines such as IL10, IL6, and TNF𝗼
[36]. Elevated levels of IL10 mRNA are consistent with
previous gene expression studies in patients during a depres-
sive episode [37], although a meta-analysis suggests that
protein concentrations of IL10 do not differ between patients
with depression and controls [38]. Previous studies have
shown no immediate change in IL10 protein levels within 24
hoursfollowingECTtreatments,althoughlevelsdiddecrease
gradually over time with multiple ECT treatments [39, 40].
In terms of mRNA, Belzeaux et al. found that IL10 levels
that were elevated prior to medical treatment did decrease
and were no longer significantly higher than controls after 8
weeks [41]. We did not evaluate another key cytokine, IL6,
in this study; however, we have previously reported that IL6
and IL10 expression increased in female patients with active
medication refractory depression [42]. IL6 mRNA decreases
following medical treatment were also linked to being a
responder in the GENDEP study [1]. These findings suggest
that immune dysregulation may be related to the etiology
of depressive symptoms. Expansion of immune markers to
include protein as well as mRNA should be considered for
future studies.
We also observed consistent treatment-related decreases
in expression of the glucocorticoid receptor, NR3C1. When
each individual patient’s response was examined, nearly all
patients (85% of ISO and 90% of ECT) displayed decreased
levels of NR3C1 24–48 hours following the last treatment.
Theglucocorticoidpathway,whichisinvolvedintheimmune
response, particularly in inhibiting inflammatory responses,
has previously been shown to be dysregulated in some
patientswithdepression[43].Animalstudieshavefoundthat
electroconvulsive stimulation (ECS) can normalize stress-
induced decreases in brain hippocampal glucocorticoid
receptor mRNA [44]. Furthermore, ECT has been shown to
normalize cortisol response in a small study of 7 patients
successfullytreatedwithECT[45].Thefindingthatdecreased
NR3C1mRNAwaspresentinbothtreatmentgroupssuggests
ISOtreatmentmayalsoaffectthisglucocorticoidpathway,in
ways similar to ECT.
The dopamine receptor DRD4 showed decreases in all
DD patients from pretreatment to posttreatment though
not versus controls. Dopamine plays an important role in
reward-seeking and motivation, the disruption of which can
lead to anhedonia. Decreases in expression of the DRD4
receptor may be compensatory changes responding to an
increased release of dopamine itself. This is potentially
important, given that dopamine mediates some bidirectional
communication between the central nervous system and
immune function [46]. In preclinical models, ECS has led
to enhanced dopaminergic function as well as upregulation
of D1 and D3 receptor binding, while decreased D2 receptor8 Depression Research and Treatment
binding has been observed in brain regions of humans
[47]. In rat studies, isoflurane anesthesia has also been
s h o w nt oi n c r e a s el e v e l so fd o p a m i n e[ 48] and modulate
subsequent dopamine release associated with psychotropic
medications [49]. Excess dopamine release and receptor
activation may lead to the decreases in DRD4 mRNA that
were observed. Prior gene expression studies found low
pretreatment DRD4 mRNA levels in medication-responsive
depressedpatientsthatnormalizedtocontrollevelsfollowing
successful treatment with the antidepressant paroxetine [50].
In other studies, DRD4 levels in postmortem brain tissue
from MDD and schizophrenia patients were found to be
elevated [51, 52]. Variations in peripheral and postmortem
levels of DRD3 and dopamine transporter have also been
observed, suggesting broad dysregulation of dopaminergic
pathways in depressive disorders [53, 54].
For the enzyme Sult1A1, DD patients displayed pretreat-
ment levels similar to those in healthy controls but still had
significant decreases at posttreatment. Sult1A1 is responsible
for the inactivation and ultimate metabolism of a number
of compounds, including hormones, catecholamines, and
drugs[55].Thus,decreasesinSult1A1mRNAandtheenzyme
product may lead to increased availability of these important
signaling molecules and medications. Though research has
shown that genetic variants of Sult1A1 can increase risk of
breastorcolorectalcancer,fewstudieshavefounddifferences
in depressive disorders [55, 56]. One study by Marazziti et al.
found variability among different mood disorders in platelet
proteinlevelsofphenosulfotransferase(PST),whichiscoded
by Sult1A1; these variations included increases in patients
with obsessive compulsive disorder and mania, decreases in
patients with MDD or migraine, and no differences with
B P Dr e l a t i v et oc o n t r o l s[ 57]. No prior study, however,
has examined patients with medication refractory DD, who
mightbeexpectedtodifferfrommedicationrespondersgiven
t h ee ff e c to fS u l t 1A 1o nd r u gm e t a b o l i s m .
4.3.FunctionsofGenesDifferingConsistentlybetweenPatients
and Controls. In contrast to the genes discussed above, three
genes showed differential expression in the current sample of
patients with refractory depression versus controls that was
not altered by treatment. The first was the diazepam binding
inhibitor (DBI), a gene that is a negative allosteric modulator
of GABAA receptors, which has previously been implicated
in both depression and anxiety [58–60]. We found DBI
mRNA levels to be significantly increased in the DD group
at pretreatment. This is in line with previous studies that
found increased levels of DBI protein in cerebral spinal fluid
(CSF) of drug-free depressed patients [59, 61]. Interestingly,
other research showed a positive correlation between levels
of DBI and the corticotrophin releasing hormone (CRH) in
depressed patients, gamblers, and controls [62]. Since GABA
receptors inhibit CRH producing cells, it is possible that
elevated levels of DBI lead to increased levels of CRH and
ultimately elevated cortisol, a common signature of HPA
dysfunctioninmanydepressedpatients[63,64].Finally,pep-
tide fragments of DBI decrease the effect of benzodiazepines
on proinflammatory cytokines following immune challenge,
suggesting that increased levels of DBI may interfere with
the anxiolytic action of benzodiazepines and their effect in
HPA regulation [65]. This finding and our own observations
support the possibility that increased DBI may be a stable
biomarker for treatment-refractory depression.
WealsofoundthatmRNAgeneexpressionfortheadren-
ergic receptor ADRA2A was decreased at both pretreatment
andposttreatmentindepressedpatientsversuscontrols,even
after controlling for an association with age. This receptor’s
primary neurotransmitter, norepinephrine (NE), has roles in
acuteandchronicstress,aswellasinmediatinginflammation
[66–68], and is one of the primary targets of NRI and SNRI
antidepressants. Previous human and animal studies have
found that depression is associated with elevated levels of
the ADRA2A receptor protein and binding sites [69–72],
though some studies suggest no change or even a decrease
in binding [73, 74]. Since mRNA levels do not necessarily
correlate with protein production, our finding of decreased
ADRA2A in medication refractory DD could be indicative
of compensation for high protein expression. Future research
that concurrently determines both ADRA2A mRNA and
protein levels in refractory DD patients is needed to confirm
this explanation.
Finally, we found consistently decreased expression of
ASIC3, a member of the acid-sensing ion-channel family.
Because of the high comorbidity of depression with pain
symptoms and the fact that antidepressants can help with
pain symptoms, it is likely that receptors that mediate the
sensationsofpainandfatiguemaybedysregulatedindepres-
sion [75, 76]. In this study, we examined two ATP-responsive
receptors from the acid-sensing ion-channel family (ASIC1
and ASIC3). In the case of the ASIC1a receptor, ASIC1a
knock-out mice and wild-type mice treated with ASIC1a
inhibitors both show antidepressant and anxiolytic behavior
[19, 77]. Previous results from our research group showed
that ASIC3 receptor expression, although normal at baseline,
wasincreasedwithin30minutesfollowingmoderateexercise
in patients with chronic fatigue syndrome (CFS) and that
its postexercise expression was positively correlated with
severityofmentalandphysicalfatigue[17].Infemalepatients
with medication refractory depression, we recently observed
dysregulated gene expression during a depressive episode
f o rt h r e eo t h e rA T P - r e s p o n s i v ei o nc h a n n e l s ,i n c l u d i n gt h e
purinergic receptors P2RX7 and P2RY1, and the transient
vanilloid receptor TRPV1 [42]. Currently, studies are under-
way to determine if metabolite detecting receptor expression
is altered in patients with depression as well as in those with
CFS following moderate exercise. If gene expression changes
u n d e r l i ee x e r c i s e - i n d u c e dp a i na n df a t i g u es y m p t o m s ,i t
may underlie depressive symptoms and therefore provide
potential treatment targets.
4.4. Implications and Need for Future Research. Blood-based
g e n ee x p r e s s i o nh a sap o s s i b l ef u t u r ei ni d e n t i fi c a t i o no fd y s -
function underlying disease and of novel treatment targets.
In this pilot study examining 9 genes, gene expression differ-
ences following both ECT and ISO treatment were noted in
patients with depression as well as pretreatment differencesDepression Research and Treatment 9
compared to controls. These preliminary results support the
involvement of neuroimmune pathways in depression and
treatment effects. This study had limited statistical power
d u et oi t ss m a l ls a m p l es i z e ,l i m i t e dg e n ea r r a y ,a n ds e v e r a l
other limitations that can only be effectively addressed by
subsequent research.
First, we only examined patients with medication refrac-
tory depression and we combined BPD and MDD patients.
Thus even for the three mRNAs that showed trait-like differ-
ences between DD patients and controls, our study cannot
determine whether these are biomarkers that distinguish
medication refractory from medication responsive patients
or based on depression diagnosis. Future studies including
both types of DD patients are needed to address this issue.
There clearly are many subtypes of depression, with unique
gene expression patterns both before and following treat-
ment. We previously reported on gene expression differences
betweenfemalepatientswithMDDandBPDaftercontrolling
for medication use and depression severity [42]. Because our
sample size was small, our findings may not generalize to
the larger population of patients with refractory depression.
It is hoped that future studies may be able to use gene
expressiontoidentifydepressionsubtypesthatmatchclinical
observations.
Secondly, we report here on gene expression 24–48
hours following treatment. In some additional data obtained
from 16 of these 22 DD patients who were also examined
4 weeks following end of treatment, there was continued
dysregulationinDBI,ADRA2A,andASIC3despitegenerally
goodmaintenanceofdepressivesymptomimprovement.This
further reinforces our preliminary interpretation that dys-
regulation in these pathways may be trait-like characteristic
in patients with medication refractory depression that could
underlie their susceptibility to symptom relapse. In contrast,
NR3C1 levels had returned to control levels after 4 weeks,
suggesting that treatment-related changes in this biomarker
may be time-dependent and unstable. Further studies are
necessary to understand the relationship between gene
expression, symptom presentation, and treatment response.
Thirdly, in our study we did not have any control subjects
that were currently taking antidepressants or other mood-
altering medications. It is therefore possible that differences
in gene expression are the result of concurrent medication
use. In fact, previous research suggests that antidepressants
[1, 78, 79], anticonvulsants [42, 80], and antipsychotics
[81] can have effects on gene expression and protein pro-
duction. Therefore, medication use should continue to be
examined for potential effects in gene expression studies,
and researchers should consider comparisons between indi-
viduals on these same medications who are not currently
experiencing a depressive episode.
Finally, this study only examined 9 genes in a candidate-
driven study. We recently completed another study examin-
ing a diverse panel of 28 genes during a depressive episode
and found further support for pretreatment dysregulation
in inflammatory pathways as well as members of metabolic
receptors, such as purinergic and vanilloid receptors [42].
Future studies with larger gene expression arrays and with
larger subgroups of patients (including both medication-
responsive and refractory bipolar and unipolar depression)
is strongly encouraged to validate our preliminary findings.
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